18 February 2011 - The US Food and Drug Administration (FDA) approved yesterday Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

The conditions for which the latest batch of products are intended are aneurismal subarachnoid haemorrhage, pulmonary arterial hypertension, multiple myeloma, iron overload, soft tissue sarcoma, and hereditary Factor XIII deficiency all, by definition, rare conditions in Europe, but all of them seriously affecting the quality of life of those who suffer from them, and all of them currently lacking adequate treatment possibilities.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.